Treace Medical Concepts, Inc.

NASDAQ•TMCI

CEO: Mr. John T. Treace

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2021-04-23

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Contact Information

100 Palmetto Park Place, Ponte Vedra, FL, 32081, United States

904-373-5940

www.treace.com

Market Cap

$87.20M

P/E (TTM)

-1.5

26.4

Dividend Yield

52W High

$8.87

52W Low

$1.31

52W Range

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$62.52M+0.00%

4-Quarter Trend

EPS

-$0.15+0.00%

4-Quarter Trend

FCF

-$10.42M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Modest Total revenue reached $212.69M in 2025, marking a modest 1.6% increase compared to 2024 results.

Sales Expense Optimization Sales and marketing expenses decreased by $6.76M, reflecting a 4.6% reduction compared to the previous year.

Surgeon Base Expansion Active surgeon base expanded by 6% to 3,337 users performing procedures across various company systems.

New Debt Financing Secured Company secured a new $175.0M senior secured loan facility in December 2025 to support operations and growth.

Risk Factors

Sustained Profitability Challenge Incurred net loss of $59.0M for 2025; achieving and sustaining profitability remains a significant challenge.

Flagship Product Dependence Revenue remains highly dependent on Lapiplasty System sales, which are experiencing slower growth due to market shifts.

Intense Market Competition Intense competition and evolving surgeon preferences for minimally invasive osteotomies negatively impact flagship Lapiplasty revenue.

Active Litigation Exposure Company faces shareholder class action and patent infringement litigation risks, potentially draining financial resources and management time.

Outlook

Next-Gen Product Launch Next-generation Lapiplasty Lightning platform is slated for commercialization in 2026, aiming for faster procedures and greater accuracy.

Sales Force Strategy Focus Strategy focuses on optimizing direct sales force structure and coordination to facilitate growth and improve long-term operating leverage.

R&D Pipeline Expansion R&D efforts focus on developing complementary products that leverage existing fixation platforms to expand market position.

Direct Education Spending Cut Management plans to reduce spending on direct-to-patient outreach programs in 2026 while maintaining brand awareness efforts.

Peer Comparison

Revenue (TTM)

EHAB

$1.06B

+2.4%

BVS

$568.09M

-0.9%

TOI

$502.73M

+27.8%

Gross Margin (Latest Quarter)

SMLR

91.5%

+0.1pp

DCTH

85.5%

+1.9pp

LAB

83.5%

-3.2pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EHAB	$689.84M	-149.9	-0.8%	42.8%
SRDX	$614.51M	-34.8	-15.6%	19.2%
BVS	$600.92M	26.1	13.8%	45.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

5.9%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

25%

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data